Pharmaceutical data

Pharmaceutical data covers drugs from development to market: pipeline assets, regulatory approvals, labels, patents and exclusivity, launches, and list or reimbursement prices. Buyers include pharma strategy and business development teams, market access and pricing groups, generic and biosimilar manufacturers, investors and health-tech builders.

Typical fields

• Drug name, active ingredient and brand names
• Originator company and licensing partners
• Indication, mechanism of action and therapeutic area
• Development stage and regulatory status by country
• Approval dates and label changes
• Patent and exclusivity expiry dates
• Pack, strength, product codes (such as NDC) and list or reimbursed price

Sources and collection

Core facts come from medicines regulators, patent offices, official price and reimbursement lists, company filings and press releases. Providers curate and standardize these sources, follow assets through name changes and licensing deals, and often add analyst commentary on probability and timing.

Delivery and pricing

Delivered through web platforms, APIs and bulk files. Pricing is usually an annual subscription driven by country coverage, depth (pipeline only versus pricing and market access), history and number of users. Multi-country price-list datasets are often priced per country or region.

Before you buy

• Check whether prices are list, net or reimbursed, and the date and currency of each price.
• Ask how quickly regulatory decisions are reflected after an agency announcement.
• Confirm how assets are tracked through renaming and licensing deals.
• Check coverage of biosimilars, generics and combination products.
• Review whether the licence allows internal analytics only or use in your own products.